DREAMLAND for Acute Myeloid Leukemia (AML)

Phase-Based Progress Estimates
Massachusetts General Hospital, Boston, MA
Acute Myeloid Leukemia (AML)+3 More
DREAMLAND - Behavioral
All Sexes
What conditions do you have?

Study Summary

This research study is evaluating whether a psychological mobile application (app), is efficacious in reducing anxiety and depression symptoms and improving quality of life for patients diagnosed with acute myeloid leukemia (AML) compared to a physical health promotion app.

Eligible Conditions

  • Acute Myeloid Leukemia (AML)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Acute Myeloid Leukemia (AML)

Study Objectives

0 Primary · 5 Secondary · Reporting Duration: Up to 6 months

Up to 6 months
Health care utilization
Up to Day 90
Anxiety Symptoms
Depression Symptoms
Post-Traumatic Stress Disorder (PTSD) Symptoms
Quality of Life in Patients with Leukemia
Symptom Burden

Trial Safety

Safety Progress

1 of 3

Other trials for Acute Myeloid Leukemia (AML)

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Active Control
Experimental Treatment

180 Total Participants · 2 Treatment Groups

Primary Treatment: DREAMLAND · No Placebo Group · N/A

Experimental Group · 1 Intervention: DREAMLAND · Intervention Types: Behavioral
ActiveComparator Group · 1 Intervention: CERENA · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 months

Trial Background

El-Jawahri Areej,M.D., Principal Investigator
Principal Investigator
Massachusetts General Hospital
Closest Location: Massachusetts General Hospital · Boston, MA
Photo of Massachusetts General Hospital  1Photo of Massachusetts General Hospital  2Photo of Massachusetts General Hospital  3
1993First Recorded Clinical Trial
46 TrialsResearching Acute Myeloid Leukemia (AML)
2425 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are receiving chemotherapy or a similar regimen requiring prolonged hospitalization.
You are able to understand and speak English.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.